"ニコチナミドモノヌクレオチドは,糖尿病前の女性の筋肉インスリン感受性を増加させる"に関するコメントへの返信
Samuel Klein1, Mihoko Yoshino2
1Center for Human Nutrition, Washington University School of Medicine, St. Louis, MO 63105, USA. sklein@wustl.edu.
まとめ
ニコチナミドモノヌクレオチド (NMN) 療法は,臨床試験で筋肉のインスリン感受性を改善した. 肝臓脂肪のベースラインの違いにもかかわらず,NMNの効果は認められた.
科学分野:
- 代謝と内分泌学
- 臨床薬理学
背景:
- ランダム化試験の評価には,ベースラインのグループ差を評価する必要があります.
- 筋肉のインスリン感受性は重要な代謝指標です.
研究 の 目的:
- ニコチナミド・モノヌクレオチド (NMN) の筋肉インスリン感受性への影響を評価する.
- ベースラインの差異がNMNの有効性に影響するかどうかを判断する.
主な方法:
- ランダム化臨床試験のデザイン
- NMN治療とプラセボの比較
- 筋肉のインスリン感受性の測定
- 肝臓内トリグリセリド値の評価
主要な成果:
- 筋肉のインスリン感度は,両方のグループで同等であった.
- プラセボと比較して,NMN療法は筋肉のインスリン感性を有意に改善しました.
- 肝臓内トリグリセリドの含有量のベースラインの違いは,筋肉に対するNMNの観察された効果を変化させなかった.
結論:
- NMN治療は,筋肉のインスリン感受性を改善する効果を示しています.
- 筋肉のインスリン感受性に対するNMNの効果は,肝臓脂肪の基準値の違いとは無関係です.
関連する概念動画
Diabetes Mellitus: Type 2 and Gestational
3.6K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
3.6K
Insulin: Dosing Regimen and Adverse Effects
329
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
329
Hormones Regulating Blood Glucose
5.2K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
5.2K
Oral Hypoglycemic Agents: Biguanides and Glitazones
361
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
361
Insulin: The Receptor and Signaling Pathways
1.8K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
1.8K
Diabetes Mellitus: Overview and Type I Subtype
4.0K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
4.0K


